Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Verastem, Inc. - Common Stock
(NQ:
VSTM
)
5.740
+0.780 (+15.73%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Verastem, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
12 Health Care Stocks Moving In Friday's Intraday Session
May 26, 2023
Via
Benzinga
Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 26, 2023
Gainers Onfolio Holdings, Inc. (NASDAQ: ONFO) gained 73% to $2.02 after the company announced it completed development of a generative AI search tool.
Via
Benzinga
Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib
May 25, 2023
From
Verastem Oncology
Via
Business Wire
Verastem: Q1 Earnings Insights
May 09, 2023
Via
Benzinga
Analyst Initiates Verastem With Neutral While 'Waiting For FDA Go-Ahead'
March 30, 2023
Via
Benzinga
Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors
May 16, 2023
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 09, 2023
From
Verastem Oncology
Via
Business Wire
Verastem Oncology to Participate in Upcoming Investor Conferences
May 01, 2023
From
Verastem Oncology
Via
Business Wire
New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting
April 26, 2023
From
Verastem Oncology
Via
Business Wire
Stocks That Hit 52-Week Lows On Wednesday
October 19, 2022
On Wednesday, 200 companies hit new 52-week lows.
Via
Benzinga
Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days
April 18, 2023
From
Verastem Oncology
Via
Business Wire
7 Very Undervalued Penny Stocks to Buy in April 2023
April 06, 2023
Undervalued penny stocks present investors who are very bullish on the near-term future with a high-risk, high-reward option.
Via
InvestorPlace
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2023
From
Verastem Oncology
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
March 30, 2023
Via
Benzinga
New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer
March 15, 2023
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
March 14, 2023
From
Verastem Oncology
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
March 06, 2023
Via
Benzinga
Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers
February 02, 2023
From
Verastem Oncology
Via
Business Wire
Why Smith Micro Software Shares Are Trading Lower By Over 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session
February 27, 2023
Gainers Lucira Health, Inc. (NASDAQ: LHDX) jumped 354% to $0.6369 after the company announced FDA authorization for its at-home combination COVID-19 & flu test.
Via
Benzinga
Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock
January 24, 2023
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
January 24, 2023
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 18, 2023
From
Verastem Oncology
Via
Business Wire
Verastem Oncology Appoints Rob Gagnon to Board of Directors
December 15, 2022
From
Verastem Oncology
Via
Business Wire
Cigna To Rally 15%? Plus Needham Slashes PT On This Stock By 40%
November 07, 2022
Raymond James raised the price target on Cigna Corporation (NYSE: CI) from $330 to $370. Raymond James analyst John Ransom maintained a Strong Buy rating on the stock. Cigna shares rose 0.1% to $322.17...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 07, 2022
Gainers Cidara Therapeutics (NASDAQ:CDTX) shares rose 14.6% to $0.64 during Monday's pre-market session. The market value of their outstanding shares is at $44.9 million. The company's, Q3 earnings...
Via
Benzinga
Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 03, 2022
From
Verastem Oncology
Via
Business Wire
10 Best Medical Stocks Under $5
October 29, 2022
The medical industry is one of the most lucrative sectors globally, and it is one that sees the highest spending in terms of research and development, and breakthrough advances through keeping up the...
Via
Talk Markets
Why Taysha Gene Therapies Shares Jumped Over 97%; Here Are 70 Biggest Movers From Yesterday
October 26, 2022
Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) surged 97.4% to close at $2.98 after Astellas Pharma Inc announced it will invest a total of $50 million to acquire 15% of the company.
Via
Benzinga
Verastem Oncology Appoints Anil Kapur to Board of Directors
October 20, 2022
From
Verastem Oncology
Via
Business Wire
Stocks That Hit 52-Week Lows On Monday
October 10, 2022
During Monday's trading, 528 companies set new 52-week lows.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.